Microrna as a cancer progression predictor and its use for treating cancer
AssigneeTaipei Veterans General Hospital
InventorsShih-Hwa Chiou, Guang-Yuh Chiou
Life of this patent
Estimating the term…
Abstract
The present invention is based on the findings that a novel function for miR142-3p in the regulation of Sox2, adenylyl cyclase 9 (AC9), and CD133 expressions, and consequently the overall stemness of recurrent GBM cells as well as CSCs, and that miR142-3p modulated tumor-initiating properties in recurrent GBM. The present invention consequently supports the development of novel miRNA-based strategies for brain tumor treatment.
Claims26
A method for suppressing the expression of a target gene in a cell, comprising introducing miR142-3p into the cell, wherein the target gene encoding CD133, Sox2, or AC9.
A method for diagnosing or predicting whether a subject has, or is at risk for developing recurrent glioblastoma multiforme after treatment, comprising:
- (a) measuring the level of miR142-3p in a control sample from the subject with primary GBM;
- (b) measuring the level of miR142-3p in a test sample from the same subject after treatment;
- and
- (c) comparing the level of miR142-3p in the test sample of step (b) to the level of miR142-3p in the control sample of step (a),
- wherein the level of miR142-3p in the test sample of step (b) lower than the level of miR142-3p in the control sample of step (a) by indicates that the subject has, or is at risk for developing recurrent glioblastoma multiforme after treatment.
A method for treating glioblastoma multiforme in a subject, comprising administering a therapeutically effective amount of miR142-3p to the subject in need thereof.
A method for producing a glioblastoma multiforme animal model, comprising:
- (a) preparing a primary glioma cell;
- (b) introducing a miR142-3p antisense oligonucleotide into the primary glioma cell to obtain a miR142-3p depleted cells;
- (c) transplanting the miR142-3p depleted cells to an animal to obtain the animal suffering from glioblastoma multiforme.
A method for increasing the sensitivity of a glioblastoma multiforme cell to radiotherapy comprising administering a therapeutically effective amount of miR142-3p to the glioblastoma multiforme cell.
Dependencies are inferred from the claim text.